The Emory Alzheimer's Disease Center (ADC) provides Georgia and surrounding states with outstanding clinical, research, and educational programs. The ADC emphasis on mild cognitive impairment (MCI) is influenced by shared interests in: i) multi-cultural issues in dementia; ii) the clinical spectrum of MCI; and iii) the role of sleep disorders in neurodegeneration. The ADC Cores (Clinical, Neuropathology, Education,also Data Management) build on renowned clinical programs and cutting-edge research. Convergent local developments bring remarkable growth to the ADC, including: one of the nation's fastest growing research enterprises; new leadership focused on neurodegeneration in the Department of Neurology, Center for Neurodegenerative Disease, and Yerkes National Primate Center; outstanding institutional support; close collaborations with the Emory-NIEHS Parkinson's Disease Center and the Center for Health in Aging; a unique industry partnership with deCODE Genetics to discover new susceptibility genes; outstanding clinical programs with a large and diverse patient populations at Wesley Woods Center and Grady Memorial Hospital, with the latter providing services and research opportunities for a predominantly African-American population; and a partnership with Dr. Bernardino Ghetti (Indiana ADC) to jointly operate the Neuropathology Core and enhance research at both institutions. Three cutting edge research projects are closely integrated with ADC Cores: Project 1 (Dr. Stuart Zola) adapts novel, highly sensitive memory tasks developed in non-human primates to ADC Clinical Core subjects; Project 2 (Dr. Allan Levey) tests the association of novel candidate genes for AD and PD, discovered in Iceland, in ADC Clinical Core subjects; and Project 3 (Dr. Junmin Peng) applies state-of-the-art proteomics technologies to MCI, AD, and PD brains characterized in the Neuropathology Core. Collectively, these projects span clinical, translational, and basic research and will advance our understanding of MCI, AD, PD, and related disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG025688-01S1
Application #
7121378
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Phelps, Creighton H
Project Start
2005-06-01
Project End
2010-04-30
Budget Start
2005-09-30
Budget End
2006-04-30
Support Year
1
Fiscal Year
2005
Total Cost
$38,639
Indirect Cost
Name
Emory University
Department
Neurology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Chalermpalanupap, Termpanit; Schroeder, Jason P; Rorabaugh, Jacki M et al. (2018) Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38:74-92
Maezawa, Izumi; Nguyen, Hai M; Di Lucente, Jacopo et al. (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141:596-612
Bishof, Isaac; Dammer, Eric B; Duong, Duc M et al. (2018) RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. J Biol Chem 293:11047-11066
Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :
Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Johnson, Erik C B; Dammer, Eric B; Duong, Duc M et al. (2018) Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13:52

Showing the most recent 10 out of 444 publications